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Introduction
Drug-delivery techniques for the treatment of sensorineural 
hearing loss (SNHL) are categorized as systemic (SIS), 
intratympanic (IT), and intracochlear (IC), each of them 
with their particular advantages and disadvantages,1,2 For 
example, although SIS is simpler, only a small amount of 
drug crosses the blood labyrinth barrier (BLB) to reach the 
inner ear,3,4 and high doses of medication must be adminis-
tered to achieve the appropriate concentration in the inner 
ear. In addition, SIS administration of drugs like corticoste-
roids has numerous negative side effects that might worsen 
patient prognosis. IT administration of pharmacological 
drugs to the middle ear has been heavily used over the past 
decades for the treatment of sudden SNHL and Meniere’s 
disease.5-10 IT administration, however, has the limitation 
that the drug must remain in the middle ear cavity and in 
contact with the round window membrane (RWM) or the 
annular ligament of the oval window for enough time to 
permeate into the cochlea.6,11 Unfortunately, drugs that 
enter the middle ear cavity are quickly discharged to the 
Eustachian tube through mucociliary flow.12,13 The required 
increase in frequency of drug administration to compensate 
this loss not only increases the inconvenience and the cost 
of therapy but also the incidence of tympanic membrane 
perforations14 and undesired infections acquired during the 
procedure.5 Finally, active IC drug delivery systems allow 
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Abstract
Objectives: Isolate, purify, and characterize extracellular vesicles (EVs) obtained from auditory HEI-OC1 cells, and 
evaluate their suitability for intracochlear transport and delivery of pharmacological drugs and/or pro-resolution mediators 
of acute inflammatory processes.
Methods: HEI-OC1 EVs were isolated and purified using the exoEasy Maxi Kit, and their size was evaluated by nanoparticle 
tracking techniques. Bottom-up proteomics of the EVs, either freshly obtained or stored for up to 4 months at −20°C, 
was performed by LC-ESI-MS/MS. LC-ESI-MS/MS-MRM was used to measure the loading of dexamethasone inside EVs 
following co-incubation at room temperature for 1 hour with and without 5 minutes sonication.
Results: Routinely, we were able to obtain purified fractions of >2 × 109 EVs/mL, with diameters varying between 50 
and 800 nm. Bottom-up proteomics showed that among the most abundant EVs proteins, 19.2% were cytoplasmic, 17.2% 
were membrane localized, 12.3% were cytosolic, and 14.6% were nucleolar. No significant differences between fresh and 
stored EVs were detected. Importantly, co-incubation of HEI-OC1 EVs (1 × 108 EVs/mL) with dexamethasone (10 mM) 
resulted in the incorporation of 10.1 ± 1.9 nM dexamethasone per milliliter of EVs suspension.
Conclusions: Altogether, the results suggest that EVs from HEI-OC1 cells could be advantageously used as biological 
nanocarriers for the delivery of specific molecules and pharmacological drugs into the inner ear.
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for better dosing control, higher drug concentrations, and 
reduced base-to-apex concentration gradients15-18 but usu-
ally require surgical procedures with all their associated 
risks.19,20 The recently emerged new avenue for the delivery 
of drugs in a sustained and controllable manner by using 
nanoparticles as drug carriers, however, has increased the 
preference for the IC approach as the drug-delivery tech-
nique of choice for the treatment of SNHL.
One major reason for the use of nanoparticles as carriers 
is that many therapeutic agents are proteins and nucleic 
acids that have short in vivo half-lives, posing significant 
challenges to successful therapeutic outcomes. This limita-
tion may be overcome by encapsulating the agent into a 
nanocarrier able to deliver it, fully active, directly into the 
target cell. Unlike other nanocarriers, such as liposomes or 
polymeric nanoparticles, extracellular vesicles (EVs) are a 
natural endogenous delivery system that transport mole-
cules while avoiding phagocytosis and degradation by mac-
rophages. Other advantages include the fact that EVs 
continuously circulate for extended periods of time within 
the body while delivering cargoes directly into the cyto-
plasm of target cells.21-24 They are not only stable, but by 
virtue of avoiding the endosomal pathway, the transfection 
efficiency for molecules such as siRNA is enhanced.25
EVs are small (30-1000 nm) membrane vesicles of endo-
somal origin that are important for intracellular communi-
cation because of their ability to transfer many different 
molecules to other cells, thereby simultaneously influenc-
ing a number of their physiological functions.21-24 EVs are 
often broadly categorized into exosomes (30-150 nm) and 
ectosomes (aka microvesicles; 100-1000 nm), a categoriza-
tion that not only refers to their different sizes but also to 
their specific origin. While exosomes are derived from the 
endosomal system through fusion of multivesicular bodies 
with the plasma membrane, ectosomes are formed through 
the direct outward budding of the plasma membrane.21 
However, distinguishing between exosomes and ectosomes 
is technically challenging since some ectosomes share with 
exosomes several major characteristics such as size, den-
sity, and membrane markers, which impose difficulties for 
their efficient separation and characterization.26,27 With 
these limitations in mind, we use the general term EVs for 
both exosomes and ectosomes.
EVs contain proteins and lipids as well as miRNA capa-
ble of regulating an assortment of genes22,23 (public online 
databases that catalogue EV-associated components, such as 
Vesiclepedia,28 EVpedia,29 and ExoCarta,30 are readily avail-
able). This unique package of information provides both 
protection and the option of simultaneous delivery of multi-
ple molecular messengers even to sites remote to the vesicu-
lar origin.31-33 More importantly, EVs can be loaded with 
specific molecules and/or pharmacological agents using 
simple procedures,34-36 stored for extended periods,37-40 and 
then used without any processing prior to administration to 
deliver their tailored cargo through many different routes, 
including oral administration and intranasal spray.41-44 This 
flexibility confers power to alter multiple signaling path-
ways simultaneously, producing results that extend beyond 
the initial exposure and making this approach more advanta-
geous than those used for traditional pharmaceuticals.
EVs are secreted by most, if not all, types of cells both in 
vivo and in vitro, and can be commonly recovered from 
 fluids such as saliva, blood, urine, and breast milk,45 as well 
as cell culture media.31-33 It is known that EVs are involved 
in many biological processes, including the maturation of 
erythrocytes, the elimination of unnecessary proteins and 
RNA, antigen presentation in immune responses, coagula-
tion, inflammation, and angiogenesis.45 These processes are 
facilitated through the EVs composition, which is based on 
that of their parental cell. Thus, we can speculate that EVs 
from auditory cells should be particularly fitted for the 
function of nanocarriers in the IC drug delivery approach 
since they would naturally be expressing molecules associ-
ated with the function and protection of the hearing organ. 
To explore this hypothesis, we decided to investigate 
whether murine auditory HEI-OC1 cells generate EVs in 
amounts sufficient for animal and human studies and 
whether they are able to incorporate pharmacological drugs 
in order to be used as nanocarriers for IC delivery. In addi-
tion, we are reporting here a preliminary proteomic charac-
terization of these EVs.
Materials and Methods
HEI-OC1 cells
Immortomouse-derived HEI-OC1 cells were grown in 
plastic cell culture dishes with DMEM (Gibco, Dublin, 
Ireland) supplemented with 10% FBS (HyClone, Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) at 33°C 
and 5% CO2 as previously described.46 Upon reaching 
approximately 80% confluence, cells were thoroughly 
washed with PBS, a new cell culture media consisting of 
DMEM supplemented with 10% exosome-depleted FBS 
(Cat. No. A2720801, Gibco-Thermo Fisher Scientific) was 
added, and culture continued. After 24 hours, the cell cul-
ture media was removed and processed for EVs isolation 
and characterization.
EVs isolation and characterization
High-purity EVs fractions were obtained from the cell cul-
ture media using the commercially available isolation kit 
exoEasy (Cat. No. 76064, Qiagen, Germantown, Maryland, 
USA) following the procedure suggested by the manufac-
turer. Concentration and size of EVs were measured with 
the nanoparticle tracking device NanoSight NS300 
(Malvern Instruments, Worcestershire, UK), and correlated 
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with protein concentration as measured by Micro BCA 
Protein Assay Kit (Pierce Biotechnology, Thermo Fisher 
Scientific).
Proteomic studies
Bottom-up proteomics was performed using well-estab-
lished protocols. Tryptic peptide samples were desalted 
using a modified version of Rappsilber's protocol47 and 
fractionated via high pH reverse phase chromatography 
(Poroshell 120, Agilent, Santa Clara, California, USA). The 
fractions were then injected onto a reverse phase nanobore 
HPLC column (AcuTech Scientific, San Diego, California, 
USA) and analyzed with in-line nanospray ionization con-
nected to a hybrid quadrupole-Orbitrap mass spectrometer 
(QE-Plus, Thermo Fisher Scientific) operating in the posi-
tive ion data-dependent collisionally activated dissociation 
mode (nLC-MS/MS).48 The data was analyzed in Proteome 
Discoverer 2.2, which provides measurements of abun-
dance for the identified peptides, and mined using mouse 
protein databases with a series of bioinformatics methods, 
including gene ontology (GO) classification and KEGG 
(Kyoto Encyclopedia of Genes and Genomes) pathway 
analysis.49,50
Loading of EVs
To investigate the incorporation of pharmacological drugs, 
EVs from HEI-OC1 cells (1 × 108 EVs/mL) were co-incu-
bated with dexamethasone (Catalog No. D4902, Sigma-
Aldrich, St. Louis, Missouri, USA) at a final concentration 
of 10 mM for 1 hour at 25°C with and without sonication 
for 5 minutes. Next, drug-loaded EVs were subjected to a 
second EVs purification step with exoEasy columns to 
remove the unloaded drug. For determining the amount of 
dexamethasone incorporated by the EVs, dried samples 
were treated with the Amplifex Keto reagent (Sciex, 
Concord, Canada; 20 µL of diluent and 20 µL of reagent, 
60°C, 90 minutes), and after drying, the samples were redis-
solved in water (50 µL). Aliquots of the solution (20 µL) 
were analyzed by LC/MS/MS with multiple reaction detec-
tion of derivatized dexamethasone (M+ 507.4 → m/z 448.3) 
using previously optimized conditions for chromatography 
and production of the molecular and fragment ion; known 
amounts of dexamethasone (0, 2.5, 25, and 250 fmol) were 
treated and analyzed in the same way. Peak intensities from 
the standards were then used to construct a standard curve, 
and the quantity of dexamethasone in each sample was 
determined by interpolation.
Results
Isolation, counting, and sizing of EVs
Although EVs’ size and concentration varied among sam-
ples, typical values were in the ranges 50 to 800 nm and 2 
× 109 to 4 × 109 EVs/mL, respectively (Figure 1). The 
presence of larger particles (>500 nm) was not a surprise 
since 0.8 µm filters were used in the process of sample 
preparation. In contrast, the sharp decrease in the number of 
EVs with diameters below ~180 nm was completely unex-
pected. To investigate this issue, we are currently perform-
ing sequential microfiltration procedures, dividing the 
original sample into fractions containing EVs of specific 
size. In the present study, however, we are only reporting 
data corresponding to the original sample of HEI-OC1 EVs.
We performed similar measurements with freshly iso-
lated EVs and samples stored for 4 months at −20°C, with 
results that suggest minimal effects of storage on EVs mor-
phology and integrity (Figure 1). For example, in addition 
to an increase in variability between replicate measure-
ments in the sample showed in Figure 1, the shift to the 
right in the size-distribution curves (mode Panel A = 358.1 
± 17.2 nm; mode Panel B = 456.9 ± 14.1 nm) and the 
slight decrease in EVs concentration (EVs concentration: 
Panel A = 3.72 × 108 ± 1.96 × 107 particles/mL, Panel B 
Figure 1. Example of NanoSight measurements. Fresh and 4-month-old (stored at −20°C) extracellular vesicles (EVs) samples were 
diluted 1:5 in PBS. (A and B) EVs values were automatically corrected with (C) PBS data. Every curve corresponds to a single sample 
evaluated by triplicate, with 749 frames/replication. Particle concentrations: Panel A: 3.72 × 108 ± 1.96 × 107 particles/mL; Panel B: 
– 3.18 × 108 ± 8.56 × 106 particles/mL; Panel C: unreliable data.
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= 3.18 × 108 ± 8.56 × 106 particles/mL) suggest the pos-
sible clustering of small vesicles into bigger aggregates.
Protein profiling of EVs
A preliminary proteomics profile identified about 850 pro-
teins belonging to HEI-OC1 EVs (Supplemental Table in 
the online version of the article). Interestingly, 69 out of the 
top 100 proteins (69%) listed in ExoCarta as those more 
frequently identified in exosomes were found in this profile, 
and this value increased to 84% (42/50) for the top 50 pro-
teins. Moreover, if we focus on the first 30 of these 100 top 
proteins listed in ExoCarta, only 4 were not detected in this 
preliminary study (26/30, 86.7%; Table 1).
Among the full set of proteins identified in our samples, 
19.2% were cytoplasmic, 17.2% localized in membranes, 
12.3% in the cytosol, and 14.6% in the nucleus (Figure 2). 
Investigating their primary function, we found that 31.0% 
were involved in protein binding, 16.4% showed catalytic 
activity, 12.6% RNA binding, and 6.6% had a structural role 
(Figure 3). Likewise, looking at their molecular function, 
we found that 21.4% were associated primarily with cell 
metabolism, 21.2% were involved in the regulation of bio-
logical processes, and 13.7% with cell organization and 
defense (Figure 4). Comparison with the proteomic profile 
of whole HEI-OC1 cells indicated, as expected, that EVs 
concentrate some proteins while others were below the 
limit of detection. No significant differences between fresh 
and stored EVs were detected (results not shown).
Loading of EVs with pharmacological drugs
Investigating the loading of HEI-OC1 EVs with dexameth-
asone (10 mM), we found that they incorporated significant 
amounts of drug by simple co-incubation at room tempera-
ture for 1 hour, followed by a second EVs purification step 
with exoEasy columns to remove the unloaded drug. The 
measured values were 10.1 ± 1.9 nM dexamethasone per 
mL of EVs suspension, and loading was not significantly 
improved by 5 minutes sonication. Similarly, no significant 
differences in drug loading between fresh and stored EVs 
were detected (results not shown).
Discussion
We are reporting here the first results of our research on 
EVs generated by murine auditory HEI-OC1 cells. Our data 
indicate that this cell line generates EVs in amounts suffi-
cient for future animal and human studies and that they are 
able to easily incorporate dexamethasone, suggesting that 
they could be ideal nanocarriers for IC drug delivery. In 
addition, the preliminary proteomic characterization of 
these EVs provided data that when compared with those 
from similar studies of EVs from different cellular origin, 
support the idea that they express a unique set of proteins, 
perhaps including some associated with the function and 
protection of the hearing organ.
Why use HEI-OC1 cells
Mesenchymal stem cells (MSCs) are known as one of the 
most prolific producers of EVs.51,52 In addition, MSCs 
derived from adipose tissue possess a natural high capacity 
to modulate both innate and adaptive immune responses,53-55 
promoting immune tolerance and facilitating inflammatory 
resolution in a paracrine manner through their EVs.56-63 
Because of that, MSC EVs are probably the most frequently 
used model for studies such as those reported here. However, 
Table 1. Twenty-Six out of the 30 (86.7%) Proteins More 
Frequently Identified in Exosomes Were Also Found Expressed 
in Extracellular Vesicles From HEI-OC1 Cells.a
Score
ExoCarta Gene Symbol
Present in
HEI-OC1 EVs?
Abundance Score in
HEI-OC1 EVs
1 CD9 No —
2 HSPA8 Yes 41
3 PDCD6IP Yes 60
4 GAPDH Yes 40
5 ACTB Yes 18
6 ANXA2 Yes 317
7 CD63 No —
8 SDCBP Yes 70
9 ENO1 Yes 52
10 HSP90AA1 Yes 13
11 TSG101 No —
12 PKM Yes 39
13 LDHA Yes 194
14 EEF1A1 Yes 44
15 YWHAZ Yes 47
16 PGK1 Yes 420
17 EEF2 Yes 57
18 ALDOA Yes 437
19 HSP90AB1 Yes 14
20 ANXA5 No —
21 FASN Yes 792
22 YWHAE Yes 26
23 CLTC Yes 202
24 CD81 Yes 248
25 ALB Yes 48
26 VCP Yes 9
27 TPI1 Yes 188
28 PPIA Yes 362
29 MSN Yes 292
30 CFL1 Yes 301
aAs listed in ExoCarta (http://exocarta.org/Archive/ExoCarta_top100_
protein_details_5.txt; Accessed January 29, 2019).
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it is currently accepted that EVs’ therapeutic value may be 
increased by their molecular composition, which is based 
on the parental cell from which they are derived. Thus, EVs 
from auditory cells could be more suited for the function of 
nanocarriers in the IC drug delivery approach than MSCs, 
since they would naturally contain molecules associated 
with the function and protection of the hearing organ.
HEI-OC1 is a murine auditory cell line generated in our 
laboratory about 15 years ago.46 Currently, with more than 
230 published research papers and reviews discussing 
results obtained with them, they are one of the most fre-
quently used auditory cell line in hearing research. In fact, 
HEI-OC1 cells have been used in studies with glucocorti-
coid-loaded nanocarriers to palliate cisplatin ototoxicity, 
and the results showed a good correlation between 
HEI-OC1 cells and live mice.64 Thus, since HEI-OC1 are 
auditory cells with an ample literature supporting their 
usefulness for hearing research, they could be a good can-
didate for generating EVs to be used as IC drug delivery 
nanocarriers.
HEI-OC1 cells as EVs producers
Although EVs’ concentration varied among samples, our 
results indicate that typical values were above 2 × 109 EVs/
mL. Ongoing experiments, however, suggest that this num-
ber could be significantly increased by collecting the cell 
culture media after 36 to 48 hours rather than the 24-hour 
period used in the experiments reported here. In addition, 
EVs’ concentration may be further enlarged by replacing 
common ultrafiltration procedures by tangential flow filtra-
tion techniques. We estimate that samples containing around 
1 × 1011 EVs/mL could be routinely obtained with these 
methodological improvements. Thus, we are confident that 
HEI-OC1 cells are able to produce EVs on a clinically 
applicable scale.
A surprising result of these preliminary study was the 
distribution of EVs by size as estimated with the nanotrack-
ing technique. As illustrated in Figure 1, there is a promi-
nent peak for particles with diameters of ~340 nm (Figure 
1A) and ~445 nm (Figure 1B). Most importantly, in both 
cases, there is a significant decrease in the concentration of 
particles with diameters below ~200 nm. This result seems 
to indicate that HEI-OC1 EVs consist mostly of ectosomes, 
with a significant lower number of exosomes. However, 
although currently considered one of the most reliable tech-
niques for counting and sizing exosomes, the nanotracking 
technique is not exempt of problems.65,66 Current experi-
ments aimed at optimizing our measurements suggest that 
Nanosight measurements are strongly dependent on the 
optical properties of the particles, which vary with their 
size. This problem is particularly evident in experiments 
such as those reported here, where the samples include par-
ticles in a very wide size range (50-800 nm). Further studies 
with sample fractions containing EVs of specific size and/
or different techniques for vesicles counting and sizing (eg, 
Tunable Resistive Pulse Sensing) are required for elucidat-
ing this issue.
In contrast, our results showing only small differences 
between fresh obtained EVs and EVs stored for 4 months at 
−20°C were expected since it was already recognized in the 
literature that EVs are relatively insensitive to freeze/thaw 
cycles.65
Proteins in HEI-OC1 EVs
As already mentioned, 69% of the 100 proteins listed in 
ExoCarta as those more frequently identified in exosomes 
Figure 2. Proteomic analysis. Characterization of proteins from HEI-OC1 EVs by cellular localization.
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were found in HEI-OC1 cells, and this value increased to 
86.7% for the first 30 in the list. Interestingly, from the gen-
erally accepted exosomes biomarkers (CD9, CD63, and 
CD81), only CD81 was definitely detected in our samples 
(Table 1). Likewise, although the annexins (ANXA) 2, 3, 4, 
and 6 are relatively abundant in HEI-OC1 EVs, 2 of the 
most common annexins found in exosomes (ANXA1 and 
ANXA5) are either expressed at low levels or not expressed 
at all. Although our study must be further extended, these 
preliminary results support the idea that EVs from auditory 
cells would have a particular molecular profile, perhaps 
associated with the function and protection of the hearing 
organ.
HEI-OC1 EVs as potential drug nanocarriers
It is already known that EVs can be loaded with specific mol-
ecules and/or pharmacological agents using simple proce-
dures.34-36 For instance, curcumin was efficiently loaded into 
exosomes after only 5 minutes of incubation at 22°C and was 
shown to mediate significant anti-inflammatory effects in sev-
eral disease models,34,42 and both microRNA (miR-150) and 
Figure 4. Proteomic analysis. Characterization of proteins from HEI-OC1 EVs by molecular function.
Figure 3. Proteomic analysis. Characterization of proteins from HEI-OC1 EVs by associated biological process.
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the antineoplastic chemotherapy drug doxorubicin were loaded 
into EVs by co-incubation at 37°C for 1 hour and 2 hours, 
respectively.39,67 Our results confirm that EVs from HEI-OC1 
cells can be loaded with pharmacological compounds (in our 
case dexamethasone) by simple co-incubation of the vesicles 
with the compound just as EVs from different cellular origin. 
Clearly, the incorporation of a given therapeutic agent into 
HEI-OC1 EVs will be strongly dependent of the particular 
physicochemical properties of the agent, and parameters such 
as time and temperature of co-incubation and drug concentra-
tion should be optimized in every case. Nevertheless, the pres-
ent results provide strong support to the idea that HEI-OC1 
EVs could be used as IC drug delivery nanocarriers.
Conclusions
Since HEI-OC1 are auditory cells able to produce abundant EVs 
and these EVs can be quickly isolated in near pure form and 
loaded with pharmacological drugs by simple co-incubation at 
room temperature, they appear to be an excellent alternative to 
MSC for studies involving the inner ear and as nanocarriers in 
IC drug delivery therapeutic approaches. Further studies, how-
ever, are still necessary to fully characterize the EVs generated 
by HEI-OC1 cells and confirm their value for current and future 
clinical strategies aimed at protecting the inner ear and prevent-
ing noise-, drug-, and age-related hearing loss.
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